Drugs that bind to overlapping regions in the peptidase domains of ACE1 and/or ACE2 and, therefore, may perturb interaction with the SARS-CoV-2 spike protein, and has more stable binding than the native substrate (i.e., predicted to release energy > 6.0 kcal/mol) and may provide additional health benefits to the COVID-19 patients by alleviating symptoms are listed in Table 2. This evidence concerns the gene LAP3 and COVID-19.